Adjuvant treatment for renal cell carcinoma: in the long run will we get the same answers?
a Fondazione IRCCS Istituto Nazionale dei Tumori , Medical Oncology , Milano , Italy.
Paolo
P
Grassi
a Fondazione IRCCS Istituto Nazionale dei Tumori , Medical Oncology , Milano , Italy.
Elena
E
Verzoni
a Fondazione IRCCS Istituto Nazionale dei Tumori , Medical Oncology , Milano , Italy.
Giuseppe
G
Procopio
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology; D017024:Chemotherapy, Adjuvant / Q000379:methods; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome
D000970:Antineoplastic Agents
Renal cell carcinoma; adjuvant therapy; immunecheckpoint inhibitors; immunotherapy; targeted agents